Profile data is unavailable for this security.
About the company
Shanghai New World Co Ltd is a China-based company mainly engaged in department store retail enterprises integrating modern department stores, tourism, leisure and entertainment comprehensive consumption. The Company operates its businesses through four segments. The Commercial segment is principally engaged in department store retail. The Pharmaceutical Industry segment is mainly engaged in the sales of various types of chinese medicinal materials, chinese patent medicines, western medicines, ginseng and antler supplements, nutritional health products and medical equipment. The Hotel Services segment is principally engaged in the operation of Radisson brand hotels managed by Radisson Hotel Group. The Company is also engaged in other businesses segment. The Company mainly operates its businesses in the domestic market.
- Revenue in CNY (TTM)1.15bn
- Net income in CNY33.59m
- Incorporated1996
- Employees1.20k
- LocationShanghai New World Co LtdNew World CastleNo. 2-88, Nanjing West RoadSHANGHAI 200003ChinaCHN
- Phone+86 2 163588888
- Fax+86 2 163582185
- Websitehttps://www.newworld-china.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tibet Weixinkang Medicine Co Ltd | 1.29bn | 248.69m | 3.45bn | 701.00 | 13.88 | 2.40 | -- | 2.67 | 0.5715 | 0.5715 | 2.96 | 3.30 | 0.7114 | 18.19 | 5.88 | 1,840,383.00 | 13.71 | 8.20 | 17.78 | 11.13 | 50.81 | 50.20 | 19.28 | 11.53 | 3.10 | -- | 0.0045 | 59.11 | -5.43 | 12.13 | 20.94 | 23.85 | -5.61 | 38.96 |
| Shanghai New World Co Ltd | 1.15bn | 33.59m | 3.63bn | 1.20k | 108.05 | 0.8633 | -- | 3.17 | 0.0519 | 0.0519 | 1.77 | 6.50 | 0.2026 | 4.62 | 7.42 | 951,798.10 | 0.5858 | 0.5242 | 0.78 | 0.7249 | 38.56 | 33.70 | 2.89 | 2.71 | 1.52 | -- | 0.1222 | 82.75 | 33.39 | -16.40 | 160.85 | -35.00 | 53.61 | -25.42 |
| Chengdu Olymvax Biopharmaceuticals Inc | 500.05m | -12.30m | 3.71bn | 471.00 | -- | 4.14 | -- | 7.41 | -0.0303 | -0.0303 | 1.23 | 2.21 | 0.3338 | 0.4197 | 1.08 | 1,061,669.00 | -1.22 | 3.17 | -1.70 | 4.68 | 93.29 | 93.00 | -3.64 | 7.44 | 1.92 | -3.90 | 0.2505 | 9.82 | -9.38 | 45.40 | -33.94 | -- | 56.47 | -- |
| Beijing Konruns Pharmaceutical Co Ltd | 954.14m | 166.44m | 3.73bn | 447.00 | 22.02 | 1.18 | -- | 3.91 | 1.06 | 1.06 | 6.05 | 19.78 | 0.2548 | 2.50 | 3.73 | 2,134,547.00 | 5.46 | 5.43 | 6.39 | 6.24 | 88.29 | 89.93 | 21.44 | 20.76 | 3.08 | -- | 0.0486 | 21.53 | 6.15 | -2.08 | 48.24 | -10.63 | 43.05 | -9.71 |
| Hunan Warrant Pharmaceutical Co Ltd | 1.45bn | 222.11m | 3.74bn | 1.16k | 16.86 | 2.10 | -- | 2.59 | 2.37 | 2.37 | 15.44 | 19.01 | 0.6713 | 1.50 | 8.93 | 1,246,491.00 | 9.31 | 11.21 | 11.21 | 14.05 | 64.09 | 69.00 | 13.88 | 13.96 | 3.02 | -- | 0.0252 | 8.05 | 10.84 | 18.50 | 15.60 | 19.02 | 24.49 | -- |
| Hainan Huluwa Pharmaceutical Grop Co Ltd | 1.81bn | 94.97m | 3.79bn | 2.47k | 39.86 | 3.29 | -- | 2.09 | 0.2374 | 0.2374 | 4.52 | 2.87 | 0.6721 | 2.88 | 3.81 | 732,708.90 | 3.80 | 5.81 | 6.29 | 9.78 | 50.33 | 58.01 | 5.66 | 7.03 | 0.8245 | 7.04 | 0.5246 | 21.74 | 25.75 | 14.13 | 24.29 | 1.16 | 46.37 | -- |
| Sinotherapeutics Inc | 368.86m | 76.25m | 3.79bn | 260.00 | 49.71 | 3.16 | -- | 10.27 | 0.1682 | 0.1682 | 0.8137 | 2.65 | 0.275 | 3.08 | 5.83 | 1,418,710.00 | 5.69 | -- | 6.09 | -- | 51.77 | -- | 20.67 | -- | 9.09 | -- | 0.00006 | -- | 21.13 | -- | -34.29 | -- | -- | -- |
| Jinyao Pharmaceutical Co Ltd | 3.66bn | 107.59m | 3.81bn | 2.68k | 35.36 | 1.26 | -- | 1.04 | 0.0984 | 0.0984 | 3.35 | 2.76 | 0.5738 | 2.28 | 9.37 | 1,365,219.00 | 2.33 | 1.91 | 4.17 | 3.40 | 42.61 | 46.33 | 4.06 | 3.31 | 0.7584 | 27.18 | 0.2064 | 44.40 | 2.55 | 9.28 | 230.60 | -4.22 | -9.58 | 9.21 |
Data as of Jul 23 2024. Currency figures normalised to Shanghai New World Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
1.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Gfund Management Co., Ltd.as of 31 Dec 2023 | 4.20m | 0.65% |
| Everbright PGIM Fund Management Co. Ltd.as of 31 Dec 2023 | 1.25m | 0.19% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 941.54k | 0.15% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 632.90k | 0.10% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 481.19k | 0.07% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 227.70k | 0.04% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 223.10k | 0.03% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 165.50k | 0.03% |
| China Fund Management Co., Ltd.as of 31 Dec 2023 | 62.80k | 0.01% |
| Sealand Securities Co., Ltd. (Investment Management)as of 31 Dec 2023 | 54.80k | 0.01% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
